Karyopharm reports first quarter 2022 financial results and highlights recent company progress

– achieved first quarter 2022 net revenues of $47.7 million, up 105% versus first quarter 2021, including $19.4 million license revenues from partners – – xpovio® (selinexor) net product revenue of $28.3 million, with a 30% increase over q1 2021 –  – preliminary data from phase 1/2 trial evaluating selinexor in combination with ruxolitinib in patients with treatment-naÏve myelofibrosis to be presented at asco 2022 – – promising results from pre-specified exploratory subgroup analysis in patients with p53 wild-type endometrial cancer from the siendo study; planning registration-enabling study targeting initiation in 2h 2022 –  – recent approvals received by partner antengene continues to expand xpovio's global reach –  – conference call scheduled for today at 8:30 a.m. et – newton, mass.
KPTI Ratings Summary
KPTI Quant Ranking